Radius wins FDA approval for osteoporosis therapy

FDA approved an NDA from Radius Health Inc. (NASDAQ:RDUS) for Tymlos abaloparatide-SC to treat postmenopausal women with osteoporosis at high risk for fracture. The company expects to launch the drug in May.

EMA is also reviewing Tymlos, a subcutaneous peptide analog of parathyroid hormone-related protein (PTHrP). Radius expects an opinion from the agency's CHMP this year...